MANNITOL 5% Drug Patent Profile
✉ Email this page to a colleague
When do Mannitol 5% patents expire, and what generic alternatives are available?
Mannitol 5% is a drug marketed by B Braun, Hospira, and Otsuka Icu Medcl. and is included in four NDAs.
The generic ingredient in MANNITOL 5% is mannitol. There are eighteen drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the mannitol profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for MANNITOL 5%?
- What are the global sales for MANNITOL 5%?
- What is Average Wholesale Price for MANNITOL 5%?
Summary for MANNITOL 5%
| US Patents: | 0 |
| Applicants: | 3 |
| NDAs: | 4 |
| Finished Product Suppliers / Packagers: | 5 |
| Raw Ingredient (Bulk) Api Vendors: | 178 |
| Clinical Trials: | 244 |
| DailyMed Link: | MANNITOL 5% at DailyMed |
Recent Clinical Trials for MANNITOL 5%
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Xiangya Hospital of Central South University | PHASE4 |
| Stanford University | PHASE1 |
| Emmanuel Carrera | PHASE2 |
Pharmacology for MANNITOL 5%
| Drug Class | Osmotic Diuretic |
| Mechanism of Action | Osmotic Activity |
| Physiological Effect | Increased Diuresis |
US Patents and Regulatory Information for MANNITOL 5%
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| B Braun | MANNITOL 5% | mannitol | INJECTABLE;INJECTION | 016080-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Otsuka Icu Medcl | MANNITOL 5% IN PLASTIC CONTAINER | mannitol | INJECTABLE;INJECTION | 019603-001 | Jan 8, 1987 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Hospira | MANNITOL 5% | mannitol | INJECTABLE;INJECTION | 016269-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| B Braun | MANNITOL 5% IN PLASTIC CONTAINER | mannitol | INJECTABLE;INJECTION | 020006-001 | Jul 26, 1993 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| B Braun | MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12% | mannitol | INJECTABLE;INJECTION | 016080-007 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for MANNITOL 5%
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Pharmaxis Europe Limited | Bronchitol | mannitol | EMEA/H/C/001252Bronchitol is indicated for the treatment of cystic fibrosis (CF) in adults aged 18 years and above as an add-on therapy to best standard of care. | Authorised | no | no | no | 2012-04-13 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
